Satellos Bioscience Inc. (MSLE)
NASDAQ: MSLE · Real-Time Price · USD
9.79
+0.04 (0.41%)
Sep 14, 2026, 4:00 PM EDT - Market closed
Satellos Bioscience Employees
As of December 31, 2025, Satellos Bioscience had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-$1,648,095
Market Cap
201.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2024 | 17 | 1 | 6.25% | 14 | 3 |
| Dec 31, 2023 | 16 | - | - | 4 | 12 |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 144 |
| Tonix Pharmaceuticals Holding | 142 |
| Voyager Therapeutics | 141 |
| Nkarta | 106 |
| Precision BioSciences | 67 |
| Neumora Therapeutics | 63 |
| Armata Pharmaceuticals | 61 |
| Korro Bio | 57 |
MSLE News
- 5 days ago - Satellos Bioscience Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 days ago - Satellos Bioscience (MSLE) Gains INN for Forazapadin Amid Unprofitable Status and Mixed Market ... - GuruFocus
- 5 days ago - Satellos Names Forazapadin As INN For Lead DMD Drug Candidate - Nasdaq
- 5 days ago - Satellos assigns forazapadin name to SAT-3247 - TheFly
- 5 days ago - Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 - Financial Post
- 5 days ago - Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 - GlobeNewsWire
- 13 days ago - Satellos to Participate in Upcoming Investor Conferences - BNN Bloomberg
- 13 days ago - Satellos to Participate in Upcoming Investor Conferences - GlobeNewsWire